• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与毛果芸香碱和 McN-A-343 相比,SNI-2011 在大鼠唾液腺中的促唾液分泌活性:一种治疗干燥综合征潜在治疗剂的鉴定。

Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome.

作者信息

Iwabuchi Y, Masuhara T

机构信息

Department of Dental Pharmacology, School of Dentistry at Niigata, Nippon Dental University, Japan.

出版信息

Gen Pharmacol. 1994 Jan;25(1):123-9. doi: 10.1016/0306-3623(94)90021-3.

DOI:10.1016/0306-3623(94)90021-3
PMID:7517901
Abstract
  1. We examined the sialogogic activities in rat major salivary glands of SNI-2011, in comparison with those of pilocarpine and McN-A-343, and we characterized the subtypes of muscarine receptors that are involved in the sialogogic responses to SNI-2011 and McN-A-343. 2. SNI-2011 at doses ranging from 1 to 10 mg/kg (i.v.) increased the secretion of saliva in a dose-dependent manner. The dose-response curves for SNI-2011 were approximately parallel to curves for pilocarpine but the potency of SNI-2011 was about 25-fold lower than that of pilocarpine. 3. The total volume of saliva secreted in response to McN-A-343 was very much less than that secreted in response to SNI-2011. 4. The salivation induced by SNI-2011 and by McN-A-343 was inhibited by various antagonists with the following rank order of potency: 4-DAMP >> pirenzepine >> AF-DX 116. 5. Our results suggest that the sialogogic effects of SNI-2011 and McN-A-343 are mediated by direct stimulation of M3 receptors in salivary glands and that SNI-2011 may prove useful in the management of xerostomia in patients with Sjögren's syndrome.
摘要
  1. 我们研究了SNI - 2011对大鼠主要唾液腺的催涎活性,并与毛果芸香碱和McN - A - 343的催涎活性进行比较,同时我们还对参与SNI - 2011和McN - A - 343催涎反应的毒蕈碱受体亚型进行了表征。2. 静脉注射剂量为1至10 mg/kg的SNI - 2011可剂量依赖性地增加唾液分泌。SNI - 2011的剂量反应曲线与毛果芸香碱的曲线大致平行,但SNI - 2011的效力比毛果芸香碱低约25倍。3. 对McN - A - 343产生反应而分泌的唾液总体积远小于对SNI - 2011产生反应而分泌的唾液体积。4. SNI - 2011和McN - A - 343诱导的唾液分泌受到各种拮抗剂的抑制,其效力顺序如下:4 - DAMP >> 哌仑西平 >> AF - DX 116。5. 我们的结果表明,SNI - 2011和McN - A - 343的催涎作用是通过直接刺激唾液腺中的M3受体介导的,并且SNI - 2011可能被证明对干燥综合征患者口干症的治疗有用。

相似文献

1
Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome.与毛果芸香碱和 McN-A-343 相比,SNI-2011 在大鼠唾液腺中的促唾液分泌活性:一种治疗干燥综合征潜在治疗剂的鉴定。
Gen Pharmacol. 1994 Jan;25(1):123-9. doi: 10.1016/0306-3623(94)90021-3.
2
Long-lasting salivation induced by a novel muscarinic receptor agonist SNI-2011 in rats and dogs.新型毒蕈碱受体激动剂SNI-2011在大鼠和犬中诱导的持久唾液分泌
Eur J Pharmacol. 1997 Nov 19;339(1):1-9. doi: 10.1016/s0014-2999(97)01338-1.
3
(+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors.(±)-顺式-2-甲基螺[1,3-氧硫杂环戊烷-5,3'-奎宁环]盐酸盐半水合物(SNI-2011,盐酸西维美林)诱导大鼠和小鼠唾液和泪液分泌:毒蕈碱型乙酰胆碱受体的作用
Jpn J Pharmacol. 1998 Nov;78(3):373-80. doi: 10.1254/jjp.78.373.
4
Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation.盐酸毛果芸香碱和西维美林对X射线照射所致大鼠口干模型下颌下腺/舌下腺唾液分泌的影响。
Arzneimittelforschung. 2003;53(5):342-50. doi: 10.1055/s-0031-1297118.
5
Benefits of long-term pilocarpine due to increased muscarinic acetylcholine receptor 3 in salivary glands.长期使用毛果芸香碱可增加唾液腺中的毒蕈碱型乙酰胆碱受体 3,从而带来益处。
Biochem Biophys Res Commun. 2018 Sep 5;503(2):1098-1102. doi: 10.1016/j.bbrc.2018.06.125. Epub 2018 Jul 3.
6
General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
Arzneimittelforschung. 2002;52(1):14-20. doi: 10.1055/s-0031-1299850.
7
General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 2nd communication: effects on somatic nervous system and on autonomic nervous system and smooth muscle.新型毒蕈碱受体激动剂SNI - 2011的一般药理学特性,一种用于干燥综合征口干症的药物。第二篇通讯:对躯体神经系统、自主神经系统和平滑肌的影响。
Arzneimittelforschung. 2002;52(2):81-8. doi: 10.1055/s-0031-1299861.
8
Use of muscarinic agonists in the treatment of Sjögren's syndrome.毒蕈碱激动剂在干燥综合征治疗中的应用。
Clin Immunol. 2001 Dec;101(3):249-63. doi: 10.1006/clim.2001.5128.
9
Effects of pilocarpine on salivary flow in patients with Sjogren's syndrome.毛果芸香碱对干燥综合征患者唾液分泌的影响。
Oral Surg Oral Med Oral Pathol. 1992 Sep;74(3):315-8. doi: 10.1016/0030-4220(92)90066-y.
10
A new medication for treatment of dry mouth in Sjögren's syndrome.一种用于治疗干燥综合征口干症状的新药。
Tex Dent J. 2001 Apr;118(3):262-6.

引用本文的文献

1
World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment.第六届世界口腔医学研讨会:药物性唾液腺功能障碍的系统评价:患病率、诊断和治疗
Clin Oral Investig. 2015 Sep;19(7):1563-80. doi: 10.1007/s00784-015-1488-2. Epub 2015 May 22.
2
Diagnosis and management of xerostomia and hyposalivation.口干症和唾液分泌减少的诊断和治疗。
Ther Clin Risk Manag. 2014 Dec 22;11:45-51. doi: 10.2147/TCRM.S76282. eCollection 2015.
3
Significant increase in salivary substance p level after a single oral dose of cevimeline in humans.
单次口服西维美林后人体唾液中P物质水平显著升高。
Int J Pept. 2013;2013:284765. doi: 10.1155/2013/284765. Epub 2013 Mar 24.
4
Review of the Pharmacological Properties and Clinical Usefulness of Muscarinic Agonists for Xerostomia in Patients with Sjögren's Syndrome.Review of the Pharmacological Properties and Clinical Usefulness of Muscarinic Agonists for Xerostomia in Patients with Sjögren's Syndrome.
Clin Drug Investig. 2002;22(2):67-73. doi: 10.2165/00044011-200222020-00001.
5
Cevimeline.西维美林
Drugs. 2008;68(12):1691-8. doi: 10.2165/00003495-200868120-00006.
6
Recent advances in the management of ocular complications of Sjögren's syndrome.干燥综合征眼部并发症管理的最新进展
Curr Allergy Asthma Rep. 2005 Jul;5(4):327-32. doi: 10.1007/s11882-005-0077-x.